Andre Larochelle

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7508815/publications.pdf

Version: 2024-02-01

55 3,096 papers citations

23 h-index

3781 citing authors

50

g-index

189801

57 all docs 57 docs citations 57 times ranked

#	Article	IF	CITATIONS
1	Identification of primitive human hematopoietic cells capable of repopulating NOD/SCID mouse bone marrow: Implications for gene therapy. Nature Medicine, 1996, 2, 1329-1337.	15.2	765
2	Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia. New England Journal of Medicine, 2017, 376, 1540-1550.	13.9	393
3	AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in nonhuman primates. Blood, 2006, 107, 3772-3778.	0.6	183
4	Rapid mobilization of hematopoietic progenitors by AMD3100 and catecholamines is mediated by CXCR4-dependent SDF-1 release from bone marrow stromal cells. Leukemia, 2011, 25, 1286-1296.	3.3	180
5	Differential Maintenance of Primitive Human SCID-Repopulating Cells, Clonogenic Progenitors, and Long-Term Culture-Initiating Cells After Incubation on Human Bone Marrow Stromal Cells. Blood, 1997, 90, 641-650.	0.6	149
6	Molecular characterisation of side population cells with cancer stem cell-like characteristics in small-cell lung cancer. British Journal of Cancer, 2010, 102, 1636-1644.	2.9	140
7	Engraftment of immune-deficient mice with primitive hematopoietic cells from \hat{l}^2 -thalassemia and sickle cell anemia patients: implications for evaluating human gene therapy protocols. Human Molecular Genetics, 1995, 4, 163-172.	1.4	92
8	Intercellular transfer to signalling endosomes regulates an ex vivo bone marrow niche. Nature Cell Biology, 2009, 11, 303-311.	4.6	90
9	Hematopoietic stem-cell behavior in nonhuman primates. Blood, 2007, 110, 1806-1813.	0.6	78
10	Treatment optimization and genomic outcomes in refractory severe aplastic anemia treated with eltrombopag. Blood, 2019, 133, 2575-2585.	0.6	77
11	Eltrombopag maintains human hematopoietic stem and progenitor cells under inflammatory conditions mediated by IFN-Î ³ . Blood, 2019, 133, 2043-2055.	0.6	76
12	Mobilization as a preparative regimen for hematopoietic stem cell transplantation. Blood, 2006, 107, 3764-3771.	0.6	70
13	Commensal microbiota drive the functional diversification of colon macrophages. Mucosal Immunology, 2020, 13, 216-229.	2.7	70
14	Development of an inducible caspase-9 safety switch for pluripotent stem cell–based therapies. Molecular Therapy - Methods and Clinical Development, 2014, 1, 14053.	1.8	59
15	In vivo selection of hematopoietic progenitor cells and temozolomide dose intensification in rhesus macaques through lentiviral transduction with a drug resistance gene. Journal of Clinical Investigation, 2009, 119, 1952-63.	3.9	53
16	Sustained high-level polyclonal hematopoietic marking and transgene expression 4 years after autologous transplantation of rhesus macaques with SIV lentiviral vector–transduced CD34+ cells. Blood, 2009, 113, 5434-5443.	0.6	48
17	Long term maintenance of myeloid leukemic stem cells cultured with unrelated human mesenchymal stromal cells. Stem Cell Research, 2015, 14, 95-104.	0.3	48
18	Human and rhesus macaque hematopoietic stem cells cannot be purified based only on SLAM family markers. Blood, 2011, 117, 1550-1554.	0.6	46

#	Article	IF	Citations
19	Bone marrow homing and engraftment of human hematopoietic stem and progenitor cells is mediated by a polarized membrane domain. Blood, 2012, 119, 1848-1855.	0.6	46
20	Functional Niche Competition Between Normal Hematopoietic Stem and Progenitor Cells and Myeloid Leukemia Cells. Stem Cells, 2015, 33, 3635-3642.	1.4	40
21	Highly multiplexed proteomic assessment of human bone marrow in acute myeloid leukemia. Blood Advances, 2020, 4, 367-379.	2.5	29
22	Hematopoietic stem cell gene therapy: dead or alive?. Trends in Biotechnology, 2005, 23, 589-597.	4.9	26
23	Genetic manipulation of hematopoietic stem cells. Seminars in Hematology, 2004, 41, 257-271.	1.8	25
24	Human hematopoietic stem cells from mobilized peripheral blood can be purified based on CD49f integrin expression. Blood, 2015, 126, 1631-1633.	0.6	23
25	Preliminary evaluation of a highly automated instrument for the selection of CD34+ cells from mobilized peripheral blood stem cell concentrates. Transfusion, 2016, 56, 511-517.	0.8	23
26	Robust generation of erythroid and multilineage hematopoietic progenitors from human iPSCs using a scalable monolayer culture system. Stem Cell Research, 2019, 41, 101600.	0.3	23
27	Hematopoietic Stem Cell Gene Therapy: Assessing the Relevance of Preclinical Models. Seminars in Hematology, 2013, 50, 101-130.	1.8	22
28	Ex Vivo Expansion of Retrovirally Transduced Primate CD34+ Cells Results in Overrepresentation of Clones With MDS1/EVI1 Insertion Sites in the Myeloid Lineage After Transplantation. Molecular Therapy, 2010, 18, 1633-1639.	3.7	20
29	Comparison of Retroviral Transduction Efficiency in CD34+Cells Derived from Bone Marrow versus G-CSF-Mobilized or G-CSF Plus Stem Cell Factor-Mobilized Peripheral Blood in Nonhuman Primates. Stem Cells, 2004, 22, 1062-1069.	1.4	18
30	Genome editing in human hematopoietic stem and progenitor cells via CRISPR-Cas9-mediated homology-independent targeted integration. Molecular Therapy, 2021, 29, 1611-1624.	3.7	17
31	Transduction of Rhesus Macaque Hematopoietic Stem and Progenitor Cells with Avian Sarcoma and Leukosis Virus Vectors. Human Gene Therapy, 2007, 18, 691-700.	1.4	15
32	Gene therapy activates EVI1, destabilizes chromosomes. Nature Medicine, 2010, 16, 163-165.	15.2	15
33	Eltrombopag promotes DNA repair in human hematopoietic stem and progenitor cells. Experimental Hematology, 2019, 73, 1-6.e6.	0.2	14
34	Genome-Wide Analysis of Off-Target CRISPR/Cas9 Activity in Single-Cell-Derived Human Hematopoietic Stem and Progenitor Cell Clones. Genes, 2020, $11,1501.$	1.0	14
35	Production and purification of high-titer foamy virus vector for the treatment of leukocyte adhesion deficiency. Molecular Therapy - Methods and Clinical Development, 2016, 3, 16004.	1.8	13
36	Transient silencing of PTEN in human CD34+ cells enhances their proliferative potential and ability to engraft immunodeficient mice. Experimental Hematology, 2012, 40, 84-91.	0.2	12

#	Article	IF	CITATIONS
37	Advances and Obstacles in Homology-Mediated Gene Editing of Hematopoietic Stem Cells. Journal of Clinical Medicine, 2021, 10, 513.	1.0	11
38	Eltrombopag Improves Erythroid Differentiation in a Human Induced Pluripotent Stem Cell Model of Diamond Blackfan Anemia. Cells, 2021, 10, 734.	1.8	11
39	NOTCH-mediated exÂvivo expansion of human hematopoietic stem and progenitor cells by culture under hypoxia. Stem Cell Reports, 2021, 16, 2336-2350.	2.3	10
40	Generation of red blood cells in vitro: monitoring the process for improved efficiency. Cytotherapy, 2013, 15, 1043-1045.	0.3	9
41	Longâ€term eltrombopag for bone marrow failure depletes iron. American Journal of Hematology, 2022, 97, 791-801.	2.0	8
42	Repetitive Busulfan Administration After Hematopoietic Stem Cell Gene Therapy Associated with a Dominant HDAC7 Clone in a Nonhuman Primate. Human Gene Therapy, 2010, 21, 695-703.	1.4	6
43	Eltrombopag combined with cyclosporine may have an effect on very severe aplastic anemia. Annals of Hematology, 2019, 98, 2009-2011.	0.8	5
44	Differential Maintenance of Primitive Human SCID-Repopulating Cells, Clonogenic Progenitors, and Long-Term Culture-Initiating Cells After Incubation on Human Bone Marrow Stromal Cells. Blood, 1997, 90, 641-650.	0.6	5
45	CD9 up-regulation on CD34+ cells with ingenol 3,20-dibenzoate does not improve homing in NSG mice. Blood, 2011, 117, 5774-5776.	0.6	4
46	No Impact of Lentiviral Transduction on Hematopoietic Stem/Progenitor Cell Telomere Length or Gene Expression in the Rhesus Macaque Model. Molecular Therapy, 2014, 22, 52-58.	3.7	4
47	Human Hematopoiesis in SCID Mice. Medical Intelligence Unit, 1995, , 197-212.	0.2	4
48	HOXB4 and retroviral vectors: adding fuel to the fire. Journal of Clinical Investigation, 2008, 118, 1350-1353.	3.9	4
49	Robust Selections of Various Hematopoietic Cell Fractions on the CliniMACS Plus Instrument. Clinical Hematology International, 2019, 1, 161-167.	0.7	2
50	Cord blood culture in hypoxia: making the cells feel at home. Cytotherapy, 2012, 14, 900-901.	0.3	1
51	Repetitive Busulfan Administration Induces Emergence of Dominant and Expanding Hematopoietic Clones with Retroviral Vector Insertion in Rhesus Macaques. Blood, 2008, 112, 3524-3524.	0.6	0
52	Culture of Mobilized Human CD34+ Cells in Hypoxic Conditions Improves Lentiviral Transduction Efficiency in SCID-Repopulating Cells. Blood, 2008, 112, 3545-3545.	0.6	0
53	siRNA-Induced Transient Silencing of PTEN Expression Enhances Human Hematopoietic Cell Engraftment in NOD/SCID/ \hat{I}^3 cnull Mice and Increases Gene Transduction Efficiency Blood, 2008, 112, 2329-2329.	0.6	0
54	Human and Rhesus Macaque Hematopoietic Stem Cells Are Not Enriched in the CD150+CD48- SLAM Population Blood, 2009, 114, 3531-3531.	0.6	0

Andre Larochelle

 #	Article	IF	CITATIONS
55	IFN- \hat{l}^3 directly inhibits the activity of erythropoietin in human erythroid progenitors. Blood Cells, Molecules, and Diseases, 2020, 85, 102488.	0.6	0